Literature DB >> 21837367

Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Ziv Gan-Or1, Anat Bar-Shira, Tanya Gurevich, Nir Giladi, Avi Orr-Urtreger.   

Abstract

A strong association was established between the GBA gene and Parkinson's disease (PD) worldwide. The most frequent GBA mutation among the Ashkenazi population (p.N370S) was previously associated with the c.1051T>C (p.F351L) alteration in the closely located MTX1 gene. We further studied the association between these two genes and its possible effect on PD. The entire coding region and exon-intron boundaries of MTX1 were analyzed in 81 PD patient carriers of GBA mutations, 15 healthy controls that carry GBA mutations, and in 25 non-carrier patients. Among them, the MTX1 c.184T>A (p.S63T) variation was detected in 93% of GBA mutation carriers (both patients and healthy controls) and in 64% of non-carrier patients (p = 0.0008). This alteration was analyzed in 600 consecutively recruited Ashkenazi PD patients and in 353 controls, all genotyped for the LRRK2 p.G2019S and GBA founder mutations. A significantly higher frequency of the MTX1 c.184A allele was found in carriers of GBA mutations compared to non-carriers (0.67 and 0.45, respectively, p < 0.0001). The homozygous MTX1 c.184A/A genotype was associated with a significantly earlier age of motor symptoms onset in patients with GBA mutations compared to other groups of patients tested (5.1-5.9 years younger, p = 0.002-0.01). A significantly higher frequency of early-onset PD (<50 years) was detected among patients carrying both GBA mutation and the homozygous MTX1 c.184A/A genotype (35.9%, compared to 13.6-17.5%, p = 0.028). Our results raise the possibility that alteration on the opposite allele, which is in trans to the GBA mutant allele, may affect the clinical course of GBA-associated PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837367     DOI: 10.1007/s10048-011-0293-6

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  41 in total

1.  Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations.

Authors:  Z Gan-Or; N Giladi; A Orr-Urtreger
Journal:  Brain       Date:  2009-06-05       Impact factor: 13.501

2.  Parkinson's disease: Mitochondrial damage control.

Authors:  Asa Abeliovich
Journal:  Nature       Date:  2010-02-11       Impact factor: 49.962

3.  PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.

Authors:  Sven Geisler; Kira M Holmström; Diana Skujat; Fabienne C Fiesel; Oliver C Rothfuss; Philipp J Kahle; Wolfdieter Springer
Journal:  Nat Cell Biol       Date:  2010-01-24       Impact factor: 28.824

4.  Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset.

Authors:  Andreas Plaitakis; Helen Latsoudis; Konstantinos Kanavouras; Beate Ritz; Jeff M Bronstein; Irene Skoula; Vasileios Mastorodemos; Spyridon Papapetropoulos; Nikolas Borompokas; Ioannis Zaganas; Georgia Xiromerisiou; George M Hadjigeorgiou; Cleanthe Spanaki
Journal:  Eur J Hum Genet       Date:  2009-10-14       Impact factor: 4.246

5.  Conserved roles of Sam50 and metaxins in VDAC biogenesis.

Authors:  Vera Kozjak-Pavlovic; Katharina Ross; Nouhad Benlasfer; Sonja Kimmig; Alexander Karlas; Thomas Rudel
Journal:  EMBO Rep       Date:  2007-05-18       Impact factor: 8.807

6.  The mitochondrial inner membrane protein mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled-coil-helix coiled-coil-helix domain-containing protein 3 and 6 and DnaJC11.

Authors:  Jing Xie; Michael F Marusich; Puneet Souda; Julian Whitelegge; Roderick A Capaldi
Journal:  FEBS Lett       Date:  2007-06-27       Impact factor: 4.124

Review 7.  The genetics of Parkinson's syndromes: a critical review.

Authors:  John Hardy; Patrick Lewis; Tamas Revesz; Andrew Lees; Coro Paisan-Ruiz
Journal:  Curr Opin Genet Dev       Date:  2009-05-04       Impact factor: 5.578

8.  Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor.

Authors:  Lorraine N Clark; Sergey Kisselev; Naeun Park; Barbara Ross; Miguel Verbitsky; Eileen Rios; Roy N Alcalay; Joseph H Lee; Elan D Louis
Journal:  Parkinsonism Relat Disord       Date:  2009-06-13       Impact factor: 4.891

9.  Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease.

Authors:  Joanne Clark; Sonika Reddy; Kangni Zheng; Rebecca A Betensky; David K Simon
Journal:  BMC Med Genet       Date:  2011-05-19       Impact factor: 2.103

10.  Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'.

Authors:  Tom R Gaunt; Santiago Rodríguez; Ian Nm Day
Journal:  BMC Bioinformatics       Date:  2007-11-02       Impact factor: 3.169

View more
  10 in total

Review 1.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

Review 2.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

3.  The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Anat Mirelman; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  J Mol Neurosci       Date:  2011-09-06       Impact factor: 3.444

4.  The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease.

Authors:  Z Gan-Or; I Amshalom; A Bar-Shira; M Gana-Weisz; A Mirelman; K Marder; S Bressman; N Giladi; A Orr-Urtreger
Journal:  J Neurol       Date:  2015-08-02       Impact factor: 4.849

5.  Detecting non-allelic homologous recombination from high-throughput sequencing data.

Authors:  Matthew M Parks; Charles E Lawrence; Benjamin J Raphael
Journal:  Genome Biol       Date:  2015-04-08       Impact factor: 13.583

Review 6.  Glucocerebrosidase and its relevance to Parkinson disease.

Authors:  Jenny Do; Cindy McKinney; Pankaj Sharma; Ellen Sidransky
Journal:  Mol Neurodegener       Date:  2019-08-29       Impact factor: 14.195

7.  Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease.

Authors:  Giulietta Maria Riboldi; Ricardo A Vialle; Elisa Navarro; Evan Udine; Katia de Paiva Lopes; Jack Humphrey; Amanda Allan; Madison Parks; Brooklyn Henderson; Kelly Astudillo; Charalambos Argyrou; Maojuan Zhuang; Tamjeed Sikder; J Oriol Narcis; Shilpa Dilip Kumar; William Janssen; Allison Sowa; Giacomo P Comi; Alessio Di Fonzo; John F Crary; Steven J Frucht; Towfique Raj
Journal:  Mol Neurodegener       Date:  2022-08-17       Impact factor: 18.879

Review 8.  Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.

Authors:  Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

9.  Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?

Authors:  Rachel Saunders-Pullman; Anat Mirelman; Cuiling Wang; Roy N Alcalay; Marta San Luciano; Robert Ortega; Deborah Raymond; Helen Mejia-Santana; Laurie Ozelius; Lorraine Clark; Avi Orr-Utreger; Karen Marder; Nir Giladi; Susan B Bressman
Journal:  Ann Clin Transl Neurol       Date:  2014-09-30       Impact factor: 4.511

10.  Genome-Wide Association of Genetic Variation in the PSCA Gene with Gastric Cancer Susceptibility in a Korean Population.

Authors:  Boyoung Park; Sarah Yang; Jeonghee Lee; Hae Dong Woo; Il Ju Choi; Young Woo Kim; Keun Won Ryu; Young-Il Kim; Jeongseon Kim
Journal:  Cancer Res Treat       Date:  2018-09-05       Impact factor: 4.679

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.